Prevalence, patterns and predictors of dyslipidaemia in Nigeria: a report from the REMAH study
- PMID: 34779815
- PMCID: PMC9364475
- DOI: 10.5830/CVJA-2021-037
Prevalence, patterns and predictors of dyslipidaemia in Nigeria: a report from the REMAH study
Abstract
Aim: The aim of this study was to determine the prevalence and predictors of dyslipidaemia in adults in Nigeria.
Methods: Using the WHO criteria, we determined dyslipidaemia using serum lipid levels of 3 211 adult Nigerians, aged at least 18 years, obtained between March 2017 and February 2018 from two communities (rural and urban) in a state from each of the six geopolitical zones of Nigeria.
Results: The overall prevalence of low high-density lipoprotein cholesterol (l-HDL), elevated low-density lipoprotein cholesterol (e-LDL), hypertriglyceridaemia (h-TG) and hypercholesterolaemia (h-CHL) were 72.5,13.6, 21.4 and 7.5%, respectively. The adjusted odds of h-CHL [odds ratio (95% confidence interval) 1.47 (1.10-1.95)], h-TG [1.89 (1.48-2.41)] and e-LDL [1.51 (1.03-2.15)] increased with obesity. Being a rural dweller increased the odds of h-TG [1.55 (1.29-1.85)], e-LDL [1.38 (1.10-1.73)] and l-HDL [1.34 (1.14-1.58)]. The odds of h-CHL [2.16 (1.59-2.95)], h-TG [1.21 (1.01-1.47)], e-LDL [1.42 (1.13-1.80)] and l-HDL [0.78 (0.65-0.93)] increased with hypertension. Diabetes mellitus doubled only the odds of h-TG [2.04(1.36-3.03)].
Conclusion: The prevalence of dyslipidaemia, particularly low HDL-C, is high among adult Nigerians.
Keywords: dyslipidaemia; elevated LDL cholesterol; hypercholesterolaemia; hypertriglyceridaemia; low HDL cholesterol; sub‐Saharan Africa.
Figures
References
-
- WHO. Global Status Report on Non-Communicable Diseases, Geneva 2014. 07-02-2020.
-
- Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA. et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation. 1995;91(9):2488–2496. - PubMed
-
- Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TRJ. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62(5):707–714. - PubMed
-
- Pol T, Held C, Westerbergh J, Lindback J, Alexander JH, Alings M. et al. Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial. J Am Heart Assoc. 2018;7(3):e007444. - PMC - PubMed
-
- Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A. et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation. 2005;112(23):3554–3561. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
